Francois Salachas

Centre De Référence Maladies Neuromusculaires Paris Est
Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications

Tofersen Treatment in SOD1-ALS: Real-World Evidence from a Retrospective Multicenter Study in France (FORSLA Study).

Tofersen Treatment in SOD1-ALS: Real-World Evidence from a Retrospective Multicenter Study in France (FORSLA Study).

Journal: Mayo Clinic proceedings. Innovations, quality & outcomes
Published: August 04, 2026

Familial, neuropathological and cellular analysis identify ARPP21 as a major amyotrophic lateral sclerosis associated gene in French cohorts.

Familial, neuropathological and cellular analysis identify ARPP21 as a major amyotrophic lateral sclerosis associated gene in French cohorts.

Journal: Acta neuropathologica
Published: May 11, 2026

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

Journal: JAMA neurology
Published: February 09, 2026

Integrative analysis of drug-gene signatures in human pluripotent stem cells reveals prazosin as a novel SQSTM1 regulator for ALS therapeutics.

Integrative analysis of drug-gene signatures in human pluripotent stem cells reveals prazosin as a novel SQSTM1 regulator for ALS therapeutics.

Journal: Stem cell reports
Published: November 25, 2025

Establishing age-stratified reference values for blood Neurofilament Light chain (NfL) using the Lumipulse® platform.

Establishing age-stratified reference values for blood Neurofilament Light chain (NfL) using the Lumipulse® platform.

Journal: Revue neurologique
Published: November 11, 2025

Neuropathological analysis of an ALS patient carrying a SOD1 missense variant and a C9orf72 repeat expansion.

Neuropathological analysis of an ALS patient carrying a SOD1 missense variant and a C9orf72 repeat expansion.

Journal: Acta neuropathologica
Published: October 14, 2025

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Journal: Lancet (London, England)
Published: October 25, 2024

Care Pathway Heterogeneity in Amyotrophic Lateral Sclerosis: Effects of Gender, Age, and Onset.

Care Pathway Heterogeneity in Amyotrophic Lateral Sclerosis: Effects of Gender, Age, and Onset.

Journal: Neuroepidemiology
Published: May 22, 2024

Dysregulation of muscle cholesterol transport in amyotrophic lateral sclerosis.

Dysregulation of muscle cholesterol transport in amyotrophic lateral sclerosis.

Journal: Brain : a journal of neurology
Published: February 16, 2024

European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD).

European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD).

Journal: European journal of neurology
Published: December 07, 2023

Clinical and genetic keys to cerebellar ataxia due to FGF14 GAA expansions.

Clinical and genetic keys to cerebellar ataxia due to FGF14 GAA expansions.

Journal: EBioMedicine
Published: October 02, 2023

Quantitative brainstem and spinal MRI in amyotrophic lateral sclerosis: implications for predicting noninvasive ventilation needs.

Quantitative brainstem and spinal MRI in amyotrophic lateral sclerosis: implications for predicting noninvasive ventilation needs.

Journal: Journal of neurology
Published: August 23, 2023
Showing 1-12 of 92

Last Updated: 09/26/2026